Compare Amgen, Inc. (AMGN) vs Morgan Stanley (MS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Morgan Stanley — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Morgan Stanley trades at $222.53 (market cap $350.60B). The key difference: Morgan Stanley is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MS | |
|---|---|---|
Market Cap | $196.12B | $350.60B |
Sector | Health | Financials |
52-Week High | $388.16 | $227.19 |
52-Week Low | $271.18 | $139.09 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Morgan Stanley (MS) trades at $222.28, up 0.07% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $57.6B in 2024 to $66.0B in 2025 and net income reaching $16.9B. Recent earnings beats and selection to lead Anthropic's IPO highlight operational strength. Technical indicators show support at $220 and resistance at $224, with RSI suggesting mild overbought conditions.
Outlook remains positive with 53.85% analyst buy ratings and $225.80 consensus price target. Key opportunities include wealth management expansion and AI integration, while risks involve volatile cash flows and rising debt-to-asset ratios. The stock offers potential upside but requires monitoring of financial leverage and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
